- Home
- RLGT vs SLS Comparison
RLGT vs SLS Comparison
Compare RLGT & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLGT
- SLS
- Stock Information
- Founded
- RLGT 2001
- SLS 2012
- Country
- RLGT United States
- SLS United States
- Employees
- RLGT N/A
- SLS N/A
- Industry
- RLGT Oil Refining/Marketing
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- RLGT Consumer Discretionary
- SLS Health Care
- Exchange
- RLGT Nasdaq
- SLS Nasdaq
- Market Cap
- RLGT 282.9M
- SLS 238.7M
- IPO Year
- RLGT N/A
- SLS N/A
- Fundamental
- Price
- RLGT $6.09
- SLS $1.96
- Analyst Decision
- RLGT Strong Buy
- SLS Strong Buy
- Analyst Count
- RLGT 1
- SLS 1
- Target Price
- RLGT $8.00
- SLS $7.00
- AVG Volume (30 Days)
- RLGT 197.6K
- SLS 4.5M
- Earning Date
- RLGT 11-11-2025
- SLS 11-12-2025
- Dividend Yield
- RLGT N/A
- SLS N/A
- EPS Growth
- RLGT 118.75
- SLS N/A
- EPS
- RLGT 0.35
- SLS N/A
- Revenue
- RLGT $902,696,000.00
- SLS N/A
- Revenue This Year
- RLGT $2.96
- SLS N/A
- Revenue Next Year
- RLGT $2.98
- SLS N/A
- P/E Ratio
- RLGT $17.37
- SLS N/A
- Revenue Growth
- RLGT 12.49
- SLS N/A
- 52 Week Low
- RLGT $5.44
- SLS $0.77
- 52 Week High
- RLGT $7.94
- SLS $2.48
- Technical
- Relative Strength Index (RSI)
- RLGT 50.33
- SLS 53.98
- Support Level
- RLGT $5.91
- SLS $1.89
- Resistance Level
- RLGT $6.12
- SLS $2.48
- Average True Range (ATR)
- RLGT 0.13
- SLS 0.16
- MACD
- RLGT 0.01
- SLS 0.00
- Stochastic Oscillator
- RLGT 75.58
- SLS 32.69
About RLGT Radiant Logistics Inc.
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.